References
- Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004; 5: 1523–1533
- Tallman M S, Hakimian D, Rademaker A W, Zanzig C, Wollins E, Rose E, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88: 1954–1959
- Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep 2006; 8: 337–342
- Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102: 810–813
- Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046–1050
- Thomas D A, O'Brien S, Bueso-Ramos C, Faderl S, Keating M J, Giles F J, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906–3911
- Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73: 412–417
- Ravandi F, Jorgensen J L, O'Brien S M, Verstovsek S, Koller C A, Faderl S, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107: 4658–4662
- Chow K U, Sommerlad W D, Boehrer S, Schneider B, Seipelt G, Rummel M J, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33–43
- Byrd J C, Peterson B L, Morrison V A, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14
- Forconi F, Sozzi E, Raspadori D, Toraldo F, Defina M, Zaja F, et al. Hairy cell leukemia (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes. Blood 2006; 108: 659a
- van Dongen J J, Langerak A W, Bruggemann M, Evans P A, Hummel M, Lavender F L, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317